IRadimed (IRMD)
Builds non-magnetic infusion, monitoring, and safety devices for MRI environments.
$85.66
vs last close−0.85 (−0.98%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 | 17 | 18 | 18 | 18 | 19 | 20 | 20 | 21 | 23 | 22 | 20 |
| Cost of revenue | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 4 | 5 | 6 | 5 | 5 |
| Gross profit | 13 | 13 | 13 | 14 | 14 | 15 | 15 | 16 | 16 | 17 | 17 | 15 |
| 7 | 8 | 9 | 8 | 8 | 9 | 9 | 9 | 10 | 10 | 10 | 9 | |
| Research & development | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 6 | 8 | 8 | 8 | 8 | 8 | 9 | 8 | 9 | 9 | 9 | 8 | |
| Selling & marketing | 3 | 3 | 4 | 3 | 4 | 5 | 4 | 4 | 5 | 5 | 4 | 4 |
| General & administrative | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 4 |
| Operating income | 6 | 5 | 5 | 6 | 6 | 6 | 5 | 7 | 7 | 7 | 7 | 6 |
| 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | |
| Other non-operating income | 0 | −1 | 0 | −1 | −1 | −1 | −1 | −1 | 0 | −1 | −1 | 0 |
| Income before tax | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 7 |
| Income tax expense | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 |
| Net income from continuing operations | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 |
| Net income | 5 | 5 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 5 |
| EPS, basic | $0.40 | $0.36 | $0.33 | $0.39 | $0.40 | $0.41 | $0.37 | $0.45 | $0.44 | $0.51 | $0.46 | $0.41 |
| EPS, diluted | $0.40 | $0.36 | $0.32 | $0.38 | $0.40 | $0.40 | $0.37 | $0.45 | $0.43 | $0.50 | $0.45 | $0.41 |
| Weighted average shares, basic | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Weighted average shares, diluted | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| EBITDA | 6 | 6 | 5 | 6 | 7 | 7 | 6 | 8 | 8 | 8 | 8 | 7 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| EBIT | 6 | 6 | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 6 |